UNITED STATES ~~SECURITIES~~ ~~AND EXCHANGE COMMISSION Washington, D.C. 20549~~

~~_________________~~SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of ~~earliest event~~1934 ~~reported): September 29, 2014~~

~~_______________________________~~Date of Report: November 25, 2014

(Date of earliest event reported)

Cortronix Biomedical Advancement Technologies, Inc.

(Exact name of registrant as specified in its charter)

_______________________________


Nevada	000-53700	98-0515701
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

8200 N.W. 41st Street, Suite 145B, Doral, FL		33166
(Address of principal executive offices)		(Zip Code)

Nevada	000-53700	98-0515701
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

(786) 859-3585

~~8200~~(Registrant’s ~~N.W.~~telephone ~~41st Street~~number, ~~Suite~~including ~~145B,~~area ~~Doral, FL 33166~~code)

(Address of Principal Executive Offices) (Zip Code)

(786) 859-3585 (Registrant’s telephone number, including area code)

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~SECTION~~Item 53.03 ~~- CORPORATE~~Material ~~GOVERNANCE~~Modification ~~AND~~to ~~MANAGEMENT~~Rights of Security Holders.

~~Item~~The ~~5.02~~disclosures ~~Departure~~set offorth in ~~Directors~~Item or5.03 ~~Certain Officers; Election~~ of ~~Directors;~~this ~~Appointment~~current ofreport ~~Certain~~on ~~Officers;~~Form ~~Compensatory~~8-K ~~Arrangements~~are ofincorporated ~~Certain~~by ~~Officers~~reference herein.

~~Resignation~~Item 5.03 Amendments to Articles of ~~Officer(s)~~Incorporation or Bylaws; Change in Fiscal Year.

~~Effective~~On ~~September~~November 3025, 2014, MrCortronix Biomedical Advancement Technologies, Inc. ~~Yoel~~(the “Company”) effected a reverse stock split (the “Reverse Split”) ~~Palomino~~of ~~resigned~~all asthe authorized and outstanding shares of the ~~President~~Company’s common stock, ~~Chief~~$.001 ~~Executive~~par ~~Officer,~~value ~~Chief~~per ~~Financial~~share ~~Officer~~(the “Common Stock”) at a ratio of one (1) share for every one hundred (100) shares outstanding, ~~Secretary~~so ~~and~~that ~~Treasurer~~every one hundred (100) shares of ~~Cortronix~~Common ~~Biomedical~~Stock before the Reverse Split represents one (1) share of Common Stock after the Reverse Split. No fractional shares ~~Advancement~~will ~~Technologies~~be issued, ~~Inc~~and no cash or other consideration will be paid. Instead, the Company will issue one whole share of the post-Reverse Split Common Stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Split. The Reverse Split becomes effective with FINRA (the Financial Industry Regulatory Authority) and in the marketplace at the open of business on December 19, 2014 (the “~~Company~~Effective Date”), whereupon the shares of Common Stock will begin trading on a split-adjusted basis. MrOn the Effective Date, the Company’s trading symbol will change to “CBATD” for a period of 20 business days, after which the “D” will be removed and the Company’s trading symbol will revert to the original symbol of “CBAT”. ~~Jorge~~In ~~Saer~~connection ~~resigned~~with asthe Reverse Stock Split, the ~~Companies~~Company’s ~~Chief~~CUSIP ~~Technology~~number ~~Officer~~will change to 220801203.

~~Appointment~~According to the Company’s Certificate of ~~Officer~~Change filed pursuant to Nevada Revised Statutes §78.209 (the “Certificate of Change”) with the Nevada Secretary of State, the maximum number of shares of Common Stock that the Company is authorized to issue was reduced from 800,000,000 to 8,000,000, and the Common Stock’s par value remained the same. The Reverse Split was effected without obtaining shareholder approval pursuant to Nevada law.

~~Effective upon~~Immediately ~~Mr.~~prior ~~Palomino’s~~to ~~resignation,~~ the Reverse ~~Board~~Split, ~~of Directors of~~ the Company ~~(the~~had ~~“Board”)~~approximately ~~appointed~~349,500,000 ~~Mr.~~shares ~~Richard~~of ~~A. Hull~~Common toStock ~~serve~~outstanding. asAfter the ~~Company’s~~Reverse ~~President~~Split, ~~Chief~~the ~~Executive~~Company has ~~Officer,~~approximately ~~Chief Financial Officer~~3,495,000 ~~Secretary~~shares ~~and Treasurer~~outstanding. ~~Richard Hull~~ ~~has~~Each ~~over~~shareholder’s 25percentage ~~years~~ownership ofin ~~experience~~the ~~working~~Company ~~with~~and ~~public~~proportional ~~companies.~~voting power Heremains isunchanged after the ~~founder~~Reverse ~~and~~Split, ~~Managing~~except ~~Member~~for ofminor ~~Maplehurst~~changes ~~Investment Group,~~and ~~LLC~~adjustments aresulting ~~Miami~~from ~~Based~~the ~~Investment~~rounding ~~Company~~of fractional interests. ~~Prior~~The torights ~~founding~~and ~~Maplehurst,~~privileges ~~Mr.~~of ~~Hull was~~ the ~~Chief~~holders ~~Operating Officer~~ of ~~Defiance Capital,~~Common ~~LLC~~Stock aare ~~Hedge~~substantially ~~Fund~~unaffected ~~Manager~~by ~~based~~the inReverse ~~New York City~~Split.

~~Mr.~~Shareholders ~~Hull~~who ~~currently~~are ~~holds~~holding their noshares ~~other~~of ~~positions with~~Common ~~the~~Stock ~~Company. There~~in iselectronic noform ~~arrangement~~at ortheir ~~understanding~~brokerage ~~pursuant~~firms todo ~~which~~not ~~Mr.~~have ~~Hull~~to ~~was~~take ~~appointed~~any action as the ~~President, Chief~~effects ~~Executive Officer, Chief Financial Officer, Secretary and Treasurer~~ of the ~~Company. Mr. Hull has no family relationships~~Reverse ~~with~~Split ~~any~~will ~~other~~automatically ~~executive~~be ~~officers~~reflected orin ~~directors~~their ofbrokerage ~~the Company or persons nominated or chosen by the Company to become directors or executive officers~~accounts. ~~There~~ isShareholders noholding ~~material~~paper ~~plan,~~certificates ~~contract~~may ~~or arrangement~~ (~~whether~~but orare not ~~written~~required to) tosend ~~which~~the ~~Mr.~~certificates ~~Hull is~~to ~~a party or in which he participates that is entered into or material amendment in connection with~~ the Company’s ~~appointment of~~transfer ~~Mr.~~agent ~~Hull,~~at orthe ~~any~~address ~~grant~~given ~~or award to Mr~~below. ~~Hull~~The ortransfer ~~modification~~agent ~~thereto,~~will ~~under~~issue ~~any~~a ~~such~~new share ~~plan,~~certificate ~~contract~~reflecting ~~or arrangement in connection with~~ the ~~Company’s~~terms ~~appointment~~ of ~~Mr. Hull. Furthermore,~~ the ~~Company~~Reverse isSplit ~~not~~to ~~aware~~each ofrequesting ~~any transaction requiring disclosure under Item 404(a) of Regulation S-K~~shareholder.

~~Appointment~~Action ofStock ~~Directors~~Transfer Corporation 2469 E. Fort Union Blvd., Suite 214 Salt Lake City, UT 84121

~~Effective~~Telephone: September 30, 2014, the Board appointed Mr. Hull as a member of the Board. There is no arrangement or understanding pursuant to which Mr. Hull was appointed as a director of the Company. It is contemplated that Mr. Hull may serve on certain committees of the Board, but no such committee appointments have been made at this time. There is no material plan, contract or arrangement (~~whether or not written~~801) ~~to which Mr. Hull is a party or in which he participates that is entered~~274-1088 ~~into~~Fax: or material amendment in connection with the Company’s appointment of Mr. Hull, or any grant or award to Mr. Hull or modification thereto, under any such plan, contract or arrangement in connection with the Company’s appointment of Mr. Hull. Furthermore, the Company is not aware of any transaction requiring disclosure under Item 404(a801) ~~of Regulation S~~274-~~K. Mr.~~1099 ~~Hull’s~~Email: ~~professional history is noted above~~info@actionstocktransfer.com

~~SIGNATURE~~Until surrender, each certificate representing shares of Common Stock before the Reverse Split would continue to be valid and would represent the adjusted number of shares of Common Stock based on the exchange ratio of the Reverse Split, rounded up to the nearest whole share. Shareholders should not destroy any stock certificate.

~~Pursuant~~All tooptions, ~~the~~warrants ~~requirements~~and convertible securities of the ~~Securities~~Company outstanding immediately prior to the Reverse Split will be appropriately adjusted by dividing ~~Exchange~~the ~~Act~~number of ~~1934,~~shares ~~the~~of ~~registrant~~Common ~~has~~Stock ~~duly~~into ~~caused~~which ~~this~~the ~~report~~options, towarrants beand ~~signed~~convertible onsecurities ~~its~~are ~~behalf~~exercisable or convertible by 100 and multiplying the ~~undersigned~~exercise ~~hereunto~~or ~~duly~~conversion ~~authorized~~price thereof by 100, as a result of the Reverse Split.

~~Cortronix~~A ~~Biomedical~~copy ~~Advancement~~of ~~Technologies,~~the ~~Inc.~~Certificate of ~~By:~~Change ~~/s/~~is ~~Richard~~attached ~~Hull~~to ~~Name:~~this ~~Richard~~current ~~Hull~~report ~~Title:~~on ~~Chief~~Form ~~Executive~~8-K ~~Officer,~~as ~~President,~~Exhibit ~~Secretary and Treasurer and Director~~3.1.

~~Date:~~Item ~~September~~9.01 ~~30,~~Financial ~~2014~~ Statements and Exhibits.

(d)

Exhibits.


Exhibit No.		Description

3.1		Certificate of Change pursuant to Nevada Revised Statutes § 78.209.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Cortronix Biomedical Advancement Technologies, Inc.

By:		Richard A. Hull
Name:		Richard A. Hull
Title:		Chief Executive Officer

Dated: __Dec. 08_, 2014

Filing Compare · Cortronix Biomedical Advancement Technologies Inc.